Amgen’s (AMGN) blinatumomab was granted FDA orphan designation as a treatment of acute lymphoblastic leukemia, according to a post to the agency’s website.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target lowered to $304 from $329 at Morgan Stanley
- FDA approves Amgen’s Uplinza for treatment of generalized myasthenia gravis
- Amgen approves UPLIZNA for treatment of generalized myasthenia gravis
- Amgen price target raised to $425 from $381 at HSBC
- Amgen management to meet virtually with Oppenheimer